diltiazem

(redirected from Cardizem cd)
Also found in: Dictionary, Thesaurus.
Related to Cardizem cd: Diltahexal, Dilacor xr, Cartia xt

diltiazem

 [dil-ti´ah-zem]
a calcium channel blocking agent that acts as a vasodilator; used as the hydrochloride salt in treatment of angina pectoris, hypertension, and supraventricular tachycardia

diltiazem

/dil·ti·a·zem/ (dil-ti´ah-zem) a calcium channel blocker that acts as a vasodilator; used as the hydrochloride salt in the treatment of angina pectoris, hypertension, and supraventricular tachycardia.

diltiazem

(dĭl-tī′ə-zĕm′)
n.
A calcium channel blocker drug, C22H26N2O4S, that acts as a coronary vasodilator and is used in the form of its hydrochloride to treat angina pectoris and hypertension.

diltiazem

[diltī′əzam]
a calcium channel blocker or calcium antagonist.
indications It is prescribed for the treatment of vasospastic and effort-associated angina, in addition to hypertension.
contraindications Sick sinus syndrome, second- or third-degree atrioventricular block, or hypotension prohibits its use.
adverse effects Among the more serious adverse reactions are edema, arrhythmia, bradycardia, hypotension, syncope, rash, headache, and dizziness.

diltiazem

Cardizem®, Tiazac® Cardiology A CCB used to the control atrial flutter or A Fib, angina, paroxysmal SVT, and HTN, which may prevent ↓ coronary artery diameter after heart transplantation Adverse effects Atrial flutter, tachyarrhythmias, slowing of AV conduction and sinus node automaticity, pruritus, sweating, constipation, N&V Contraindications WPW syndrome, constipation, peripheral edema, left ventricular dysfunction. See Calcium channel blocker.

diltiazem

A calcium channel blocker drug used in the treatment of ANGINA PECTORIS and high blood pressure (HYPERTENSION). Brand names are Adizem SR, Adizem-XL, Angitil SR, Angitil XL, Dilzem SR, Dilzem XL, Slozem, Tildiem, Tildiem LA, Viazem XL, Zemtard and Zildil SR.

diltiazem

a calcium-channel blocking agent used to produce peripheral and coronary vasodilation in the management of heart disease.
References in periodicals archive ?
138) The agreement provided that Andrx would refrain from marketing a generic version of Cardizem CD in the United States until the earliest of: "(1) Andrx obtaining a favorable, final and nonappealable determination in the patent infringement case; (2) HMR and Andrx entering into a license agreement; or (3) HMR entering into a license agreement with a third party.
and In re Cardizem CD would continue to be unlawful under the Preserve
Cardizem CD is widely prescribed for treatment of chronic chest pains, high blood pressure and prevention of heart attacks and strokes.
The delay in the availability of the generic form of Cardizem CD meant that consumers, medical insurance companies and the government were forced to purchase the higher priced brand name version of the drug for at least an extra year.
The plaintiffs in Cardizem CD and Hytrin argued that the interim agreements should be deemed per se unlawful as a market allocation scheme and the respective district courts agreed.
Aventis subsequently dropped the patent litigation and canceled the Cardizem CD contract with Andrx.
Cardizem CD, which according to IMS data had 1998 United States sales of approximately $640 million, is expected to be the largest selling product of Aventis.
Andrx also was the first company to receive FDA approval for a bioequivalent version of Cardizem CD, the subject of the patent infringement litigation initiated by HMRI and now the class action suits.
If generic Prilosec achieves the same market share as Andrx' generic copy of Cardizem CD, it likely would achieve sales for Andrx of about $625 million during its first six months on the market.